FDA Finds Beckman Coulter Troponin Test Modified Without Proper Clearance
This article was originally published in The Gray Sheet
Executive Summary
Beckman Coulter will likely need to restrict use of its AccuTn1 troponin test kit in response to FDA findings that the firm modified the assay without proper clearance, the company said March 22